Fabric Genomics alternative · for digital pathology vendors, reference labs, health systems running multi-lab sequencing
Fabric Genomics alternative for vendors who don't want their NGS interpretation owned by a competing lab
UNMIRI · See the NGS Interpretation API
On April 16, 2025, GeneDx acquired Fabric Genomics for $33M cash plus up to $18M in earnouts. Fabric operates as a GeneDx subsidiary, continuing to sell Fabric Enterprise (variant calling + ACMG/AMP classification + reporting) and powering "GeneDx Infinity," GeneDx's global exome/genome offering. Fabric was called out as a 2025 revenue contributor in GeneDx's Q4 results.
The acquisition is the story. Fabric is now owned by a clinical laboratorythat competes with the very labs and platforms Fabric used to sell to. UNMIRI is a vendor-neutral infrastructure layer with no lab business, no plan for one, and no channel conflict — selling NGS interpretation as an API, not as part of a lab's commercial strategy.
At a glance
| Dimension | Fabric Genomics | UNMIRI |
|---|---|---|
| Ownership | GeneDx subsidiary since 2025-04-16. GeneDx runs a clinical lab. | Independent. UNMIRI LLC, no lab business. Pure infrastructure provider. |
| Primary product | Fabric Enterprise: secondary + tertiary analysis, GEM (AI prioritization), ACE (ACMG classification), reporting | Cross-vendor NGS report parsing + FHIR Genomics R4 output (Engine 1) + genomics-aware CDS (Engine 2) |
| Buyer fit | Hospital labs running their own assay, national sequencing programs (NHS Genomics England, etc.), reference labs | Vendors that don't run the assay: EHR companies, digital pathology platforms, oncology CDS tools |
| Lab-competitor risk | Customer data and ACMG decision logic flow through software owned by a direct lab competitor (GeneDx) | No lab business, no competing service. Vendor-neutral by structure, not just by promise. |
| Maturity | Decade of clinical deployments, peer-reviewed validation, FDA / CE-IVDR experience | Pre-pilot. Architecture is in place. AWS BAA active 2026-05-09. Honest about stage. |
| Pricing | Enterprise, mid-five to mid-six figures annually depending on volume | $30-150K ACV mid-market, $250-750K top-tier |
The channel-conflict angle in plain terms
Before April 2025, this comparison would have led on product fit and pricing. The acquisition changed the question. A digital pathology platform routing its customers' sequencing data through Fabric is now routing it through a GeneDx subsidiary. If those customers also send sequencing to GeneDx, fine. If they intentionally send to a competing reference lab to avoid GeneDx, the data path is now a problem.
UNMIRI doesn't solve every problem Fabric does — Fabric's clinical maturity, regulatory paperwork, and validation depth are real. But for buyers where vendor neutrality is a hard requirement, the question stops being "which platform is better" and becomes "which platform isn't owned by a lab."
When Fabric Genomics is the right pick
- You're a hospital genomics program or population-scale sequencing initiative buying a full secondary-to-tertiary platform from a vendor with regulatory track record.
- You don't have channel-conflict concerns — you're a lab running your own assay, and a competing-lab-owned platform doesn't change your buying calculus.
- You need clinical-grade validation paperwork (FDA / CE-IVDR documentation) on the interpretation engine itself.
- You want GeneDx's balance sheet behind the platform.
When UNMIRI is the right pick
- You're a digital pathology vendor (Paige, PathAI, Proscia, Indica) or an EHR / CDS tool — you don't run sequencing, you consume someone else's reports, and you don't want your customers' data routed through a competing lab's subsidiary.
- You run sequencing through multiple labs (Foundation, Tempus, Caris, Guardant, in-house) and want a normalization layer that doesn't tilt toward any one of them.
- You want an open data contract you can audit before signing — the FHIR Genomics schema is on GitHub, CC-BY 4.0.
- Your compliance team is going to ask about the data path. "It's owned by a lab competitor" generates more questions than "vendor-neutral infrastructure provider, no lab business."
Frequently asked questions
- Is the channel-conflict concern overblown?
- Depends on the buyer. A health system that uses one lab and doesn't compete with GeneDx may not care. A digital pathology platform with customers who deliberately use lab-A over lab-B is going to get the question from procurement: "why is our data going through a competing lab's subsidiary?" There's no good answer.
- What about Fabric's clinical validation?
- Real and substantial. Fabric has a decade of clinical deployments and peer-reviewed validation on GEM and ACE. UNMIRI is pre-pilot. If your evaluation framework weights established clinical validation above channel neutrality, Fabric wins. If it weights both, the choice depends on your specific buyer politics.
- Will the acquisition affect Fabric's product direction?
- GeneDx has signaled Fabric continues as an independent platform business that also powers GeneDx Infinity. Whether that independence holds when the parent company makes hard strategy calls is the question every customer should ask their account team. UNMIRI's structural answer to that question is "we have no lab business to favor."
- Is UNMIRI on the same regulatory path?
- Different posture. UNMIRI is positioned as clinical decision support and report-rendering infrastructure, not a CAP/CLIA-validated diagnostic. SOC 2 Type 1 readiness assessment is targeted Q4 2026, Type 2 audit Q1 2027 contingent on first design-partner agreement. We don't claim FDA paperwork we don't have.
Talk to us about Engine 1 + Engine 2
Inspect the open FHIR Genomics schema on GitHub first. The data contract is verifiable before any NDA.